8-K: XOMA Completes Turnstone Biologics Acquisition

XOMA Royalty Corporation has successfully completed its tender offer and subsequent merger with Turnstone Biologics Corp., acquiring all outstanding shares for cash and contingent value rights.

Summary

• XOMA Royalty Corporation (XOMA) completed the acquisition of Turnstone Biologics Corp. (Turnstone) on August 11, 2025, following a tender offer.
• The tender offer, which expired on August 7, 2025, resulted in 17,192,002 shares of Turnstone common stock being validly tendered, representing approximately 74% of outstanding shares.
• The acquisition price per share was $0.34 in cash (Cash Amount) plus one non-transferable contractual contingent value right (CVR).
• The CVRs represent the right to receive potential future cash payments from 'CVR Proceeds'.
• CVR Proceeds include a 'Legacy Receivable Amount' of up to $850,000 from Canadian tax receivables (excluding $55,610 Quebec SR&ED amount) and up to $260,000 from a sublease security deposit return.
• CVR Proceeds also include any 'Net Cash Excess' if Turnstone's final net cash (recalculated 180 days post-merger) exceeds its closing net cash.
• Turnstone's outstanding restricted stock units (RSUs) vested in full immediately prior to the tender offer closing and were cancelled in exchange for the Offer Price (cash + CVR).
• All outstanding Turnstone stock options were cancelled and terminated without consideration.
• The merger was completed under Section 251(h) of the Delaware General Corporation Law, requiring no stockholder vote.
• XOMA assumed Turnstone's obligations under the Moffitt Asset Purchase Agreement, dated June 26, 2025.

Sentiment

Score: 7

Explanation: The filing indicates the successful completion of a strategic acquisition for XOMA, which is a positive operational milestone. The inclusion of CVRs offers potential upside for former Turnstone shareholders, mitigating some of the impact of the low cash price. The transaction appears to have proceeded as planned without significant negative surprises or delays.

Positives

• The successful completion of the tender offer with 74% of shares tendered indicates strong shareholder acceptance.
• The inclusion of Contingent Value Rights (CVRs) provides former Turnstone shareholders with potential future cash payments based on specific financial outcomes, offering an upside beyond the initial cash payment.
• The acquisition of Turnstone's assets, including the Moffitt Asset Purchase Agreement, could enhance XOMA's royalty portfolio.

Negatives

• Turnstone stock options were cancelled without consideration, negatively impacting option holders.
• The cash component of the offer price was relatively low at $0.34 per share, which might be seen as a negative for Turnstone shareholders seeking immediate liquidity at a higher valuation.

Risks

• The CVRs are non-transferable, limiting liquidity for holders.
• The CVRs are highly speculative, and there is no assurance that holders will receive any payments.
• The value of CVRs depends on the realization of 'Legacy Receivable Amount' (tax refunds, sublease deposit) and 'Net Cash Excess', which are subject to future determination and collection.
• The 'Wind-Down Process' for Turnstone's operations and R&D activities involves estimated costs that could impact the 'Closing Net Cash' and thus the 'Net Cash Excess' component of CVRs.
• Potential for stockholder litigation related to the transactions, which could incur costs, although the company has provisions for defense and settlement.

Future Outlook

The future outlook for former Turnstone shareholders includes potential contingent cash payments via CVRs, dependent on the realization of specific tax receivables, a sublease security deposit return, and any net cash excess from Turnstone's operations after the merger. XOMA intends to wind down Turnstone's operations and R&D activities, focusing on the acquired assets and royalty streams.

Management Comments

• Owen Hughes, Chief Executive Officer of XOMA Royalty Corporation, signed the 8-K filing, indicating his role in the completion of the merger.

Industry Context

This acquisition represents a strategic move by XOMA Royalty Corporation, a company focused on acquiring royalty streams, to integrate Turnstone Biologics Corp.'s assets. This aligns with a broader trend in the biopharmaceutical industry where specialized royalty companies seek to acquire and monetize intellectual property and revenue streams from other biotech firms, particularly those undergoing strategic shifts or winding down certain operations. The contingent value rights mechanism is a common tool in such transactions to bridge valuation gaps and provide former shareholders with exposure to future asset performance.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in this acquisition is a common mechanism in biotech and pharmaceutical M&A, particularly when there is uncertainty regarding the future value of specific assets or when a company is being acquired primarily for its intellectual property or specific revenue streams, rather than its ongoing operations.
• The tender offer success rate of approximately 74% is above the typical minimum tender condition (often 50% + 1 share), indicating strong shareholder support for the transaction, which is a positive sign for deal certainty compared to transactions with lower acceptance rates.
• The cancellation of stock options without consideration, while potentially negative for option holders, is not uncommon in acquisitions where the per-share cash consideration is low and the company is winding down operations, as it simplifies the capital structure post-acquisition.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions existing stockholder litigation (as contemplated in Section 7.07 of the Merger Agreement), including demand letters seeking supplemental disclosures or books and records under DGCL Section 220, relating to the Transactions. XOMA has rights to participate in and direct negotiations/proceedings, and consent to settlements.

Related Party Transactions

• No new related party transactions were disclosed beyond what was in the Company's proxy statement filed April 22, 2024, and the Moffitt Asset Purchase Agreement.

Stakeholder Impact

• **Shareholders (Turnstone)**: Received $0.34 cash per share and one non-transferable CVR, offering potential future contingent payments. Stock option holders received no consideration.
• **Shareholders (XOMA)**: XOMA acquired Turnstone's assets and royalty streams, potentially enhancing its portfolio.
• **Employees (Turnstone)**: The company will undergo a 'Wind-Down Process' of operations and R&D activities, which implies significant employee terminations. Restricted Stock Units vested, but stock options were cancelled.
• **Creditors/Suppliers (Turnstone)**: The wind-down process will involve settling remaining contractual obligations and liabilities, which are factored into the 'Closing Net Cash' calculation for CVRs.

Next Steps

• XOMA will cause Turnstone's securities to be de-listed from Nasdaq and de-registered under the Exchange Act as promptly as practicable, no more than 10 days after the Merger Closing Date.
• Parent will recalculate 'Final Net Cash' within 180 days following the Merger Closing Date to determine any 'Net Cash Excess' for CVR payments.
• CVR payments will be made no later than 30 days following the final determination of 'Net Cash Excess' or receipt of 'Legacy Receivable Amount', aggregated until $500,000 (except for final payment).
• The 'Wind-Down Process' for Turnstone's operations and R&D activities will continue, consistent with applicable contracts, laws, and ethical practices.

Key Dates

Keywords

Acquisition, Merger, Tender Offer, Contingent Value Rights, CVR, Biologics, Royalty, SEC Filing, Corporate Action, Shareholder Value, Asset Purchase